DEL PAPA, BEATRICE
 Distribuzione geografica
Continente #
NA - Nord America 1.288
EU - Europa 1.144
AS - Asia 296
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 2.737
Nazione #
US - Stati Uniti d'America 1.286
IT - Italia 342
IE - Irlanda 290
HK - Hong Kong 120
CN - Cina 98
SE - Svezia 98
UA - Ucraina 97
DE - Germania 89
FI - Finlandia 56
VN - Vietnam 51
RO - Romania 40
GB - Regno Unito 37
RU - Federazione Russa 34
BE - Belgio 17
FR - Francia 17
TR - Turchia 12
AT - Austria 7
CH - Svizzera 6
CI - Costa d'Avorio 5
UZ - Uzbekistan 5
SG - Singapore 4
GR - Grecia 3
PL - Polonia 3
CA - Canada 2
CZ - Repubblica Ceca 2
KR - Corea 2
LB - Libano 2
NL - Olanda 2
BG - Bulgaria 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
EU - Europa 1
GH - Ghana 1
ID - Indonesia 1
IM - Isola di Man 1
JP - Giappone 1
SC - Seychelles 1
Totale 2.737
Città #
Chandler 294
Dublin 290
San Mateo 193
Perugia 168
Hong Kong 120
Ann Arbor 70
Jacksonville 54
Dong Ket 51
Altamura 48
Medford 46
Princeton 45
Beijing 41
Bucharest 40
Andover 38
Wilmington 36
Lawrence 35
Foligno 33
New York 25
Helsinki 24
Dearborn 21
Redwood City 19
Brussels 17
Los Angeles 13
Des Moines 12
Norwalk 12
Assisi 11
Izmir 11
Woodbridge 10
Falls Church 8
Houston 8
Saint Petersburg 8
San Paolo di Civitate 8
Ashburn 6
Vienna 6
Abidjan 5
Bastia 4
Redmond 4
Shanghai 4
Aurora 3
Collazzone 3
Guangzhou 3
Moscow 3
Rome 3
Singapore 3
Auburn Hills 2
Boardman 2
Bologna 2
Changsha 2
Chicago 2
Frankfurt Am Main 2
Lappeenranta 2
Macerata 2
Melissa 2
Selargius 2
Seoul 2
West Jordan 2
Apo 1
Battipaglia 1
Bekasi 1
Campobasso 1
Catania 1
Civitanova Marche 1
Copenhagen 1
Dallas 1
Den Haag 1
Douglas 1
Fremont 1
Groningen 1
Hanover 1
Hefei 1
Jinan 1
Kocaeli 1
L'aquila 1
Latina 1
London 1
Ludwigshafen 1
Madrid 1
Montreal 1
Nanjing 1
Ottawa 1
Paris 1
San Benedetto Del Tronto 1
San Diego 1
Sassari 1
Shenzhen 1
Simi Valley 1
Sofia 1
Spello 1
Tokyo 1
Totale 1.913
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 121
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 109
Engineering donor mesenchymal cells with IL-7 hastens naive T cell recruitment. 108
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 104
Engineering donor mesenchymal cells with IL-7 hastens naive T cell recruitment in vitro and supports immunologic reconstitution after HSCT in NOD/SCID mice 90
Mesenchymal cells: a vehicle for gene therapy 84
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 81
γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and Notch down-regulation. 75
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 75
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 74
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 66
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 65
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 65
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 65
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 64
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 63
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 62
T regulatory cell separation for clinical application. 61
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 60
Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone.Di Ianni M, Moretti L, Del Papa B, De Ioanni M, Bonifacio E, Falzetti F, Tabilio A. 60
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 59
Engineering mesenchymal cells with interleukin 7 gene: effects on T cell. 18-23. 59
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 56
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 54
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse 52
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 51
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 51
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 49
A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders 49
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 49
IL-7 engineered donor stromal cells in vitro: a new approach for hastening naive T cell recruitment. 48
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 47
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse 47
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 47
New mechanism of lymphoma-induced bone marrow aplasia 47
Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. 46
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 45
Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line 43
Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. 39
Mesenchymal cells recruit and regulate T regulatory cells. 38
null 37
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 37
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 36
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 35
NOTCH and Graft-Versus-Host Disease 30
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 29
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 26
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 25
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 23
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 23
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 20
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 17
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 15
Totale 2.881
Categoria #
all - tutte 10.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.694


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 0 25 0
2019/2020220 7 2 15 7 15 21 20 12 27 70 8 16
2020/2021370 9 15 21 16 104 32 27 4 38 14 31 59
2021/2022605 12 174 8 21 14 6 9 124 4 55 81 97
2022/2023910 48 169 8 82 75 83 0 45 346 1 35 18
2023/2024355 19 44 27 23 2 17 137 6 16 20 44 0
Totale 2.881